NXP900
Small Molecule Target: SRC, YES1
Nuvectis Pharma
Most recent annual filing: 2026-02-11
- NXP900 Ph1 readoutby the end of this yearNXP900 Ph1 readout, by the end of this year, material
- NXP200 Ph1 readoutOct 23–27, 2026NXP200 Ph1 readout, Oct 23–27, 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
Ciprocopan
ciprocopan · NXP100 · HSK39297 Small Molecule Target: Complement Factor B, Factor B
NXP200
HSK42360 Small Molecule Target: BRAF
Discontinued (1)
- NXP800 — Ovarian Cancer · following the completion of a Phase 1b clinical study, we decided to cease clinical development of NXP800
Biotech Distilled coverage (8)
- 2026-08-22 UPDATE: Nuvectis Pharma (NVCT) - A $200M Shelf and a Jefferies ATM, Seven Weeks After “Runway Into 1H 2029” 🔒 Paid
- 2026-08-07 UPDATE: Nuvectis Pharma (NVCT) - The Empty Register Just Got Its First Name 🔒 Paid
- 2026-08-05 UPDATE: Nuvectis Pharma (NVCT) - The Summer Binary Just Quietly Became a Winter Footnote 🔒 Paid
- 2026-07-24 UPDATE: Nuvectis Pharma (NVCT) - The Portfolio Anchor Just Cleared a Regulator 🔒 Paid
- 2026-06-30 UPDATE: Nuvectis Pharma (NVCT) - The Financing Print I Was Waiting For 🔒 Paid
- 2026-06-30 UPDATE: Nuvectis Pharma (NVCT) - The Deal Priced Below My Yellow Flag 🔒 Paid
- 2026-06-23 UPDATE: Nuvectis Pharma (NVCT) - The One-Asset Company Just Bought Two More 🔒 Paid
- 2026-06-02 Nuvectis Pharma (NVCT) — Scientific Deep Dive for NXP900 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.